Bob Burrows | Vice President-Investor Relations |
Dan Abdun-Nabi | Chief Executive Officer |
Bob Kramer | President and Chief Operating Officer |
Rich Lindahl | Chief Financial Officer |
Atul Saran | Executive Vice President, Corporate Development and General Counsel |
Doug White | Senior Vice President, Devices Business Unit Head |
Abby Jenkins | Senior Vice President, Vaccines & Anti-infectives Business Unit Head |
Brandon Folkes | Cantor Fitzgerald |
Dana Flanders | Goldman Sachs |
Jessica Fye | JPMorgan |
Boris Peaker | Cowen |
Sameer Kandola | Wells Fargo Securities |
Keay Nakae | Chardan |
Francois Brisebois | Laidlaw |
Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2018 Emergent BioSolutions Incorporated Earnings Conference Call. At this time all participants are in a listen-only mode. Later, we will conduct the question-and-answer session and instructions will be given at that time. [Operator Instructions] I would now like to turn the conference over to Bob Burrows, VP of Investor Relations.
You may begin.